Juno Therapeutics

Juno Therapeutics

Juno Therapeutics was founded in 2013 by Hans Bishop, Larry Corey, Cary Pfeffer, and Mark J. Litton, emerging from Seattle's Fred Hutchinson Cancer Research Center. The company focused on developing chimeric antigen receptor (CAR) T-cell therapies and T-cell receptor (TCR) therapies for hematologic cancers, with early lead programs including JCAR015 for acute lymphoblastic leukemia. Juno's strategy centered on a deep pipeline of engineered cell therapies, targeting defined molecular pathways such as CD19 and other tumor antigens. The firm conducted clinical trials across the US and Europe, holding investigational new drug applications with the FDA. As a publicly traded entity from 2014 (NASDAQ: JUNO), it disclosed financials and pipeline updates via SEC filings, including the $265M IPO in December 2014 (per the firm's S-1). Stage coverage spanned preclinical through Phase 2 clinical trials, funded by venture capital from Arch Venture Partners, Flagship Ventures, and others. By 2017, Juno employed over 500 professionals in Seattle, New York, and other sites, with a 320,000-square-foot manufacturing facility in Bothell, Washington. The company had no adjacent philanthropic or operating-company vehicles disclosed beyond its core drug development operations. In March 2018, Celgene Corporation announced an acquisition of Juno for $9 billion in cash, which closed in March 2018 (per Celgene press release, March 2018). Juno's structural differentiator was its origins in academic licensing from Fred Hutch and other research institutions, creating a consortium model that integrated academic and commercial drug development. The firm's post-acquisition role as a Celgene subsidiary positioned it within a large pharmaceutical context, distinct from venture-backed or family-office-run biotech firms.